

# On the relationship between pain variability and relief in randomized clinical trials

Siddharth Tiwari<sup>1,2</sup>, Andrew D. Vigotsky<sup>2,3</sup>, A. Vania Apkarian<sup>2,4</sup>

<sup>1</sup> Illinois Mathematics and Science Academy, Aurora, IL

<sup>2</sup> Center for Translational Pain Research, Feinberg School of Medicine, Northwestern University, Chicago, IL

<sup>3</sup> Departments of Biomedical Engineering and Statistics, Northwestern University, Evanston, IL

<sup>4</sup> Departments of Neuroscience, Anesthesia, and Physical Medicine & Rehabilitation, Feinberg School of Medicine, Northwestern University, Chicago, IL

## 1. Background

- To ensure a statistically significant drug effect, clinicians and pain researchers look to exclude high “placebo responders” before the intervention phase of randomized clinical trials.
- Higher placebo response (or greater relief in the placebo group) in patients enrolled in randomized clinical trials is associated with higher baseline pain variability.
- Previous research on this relationship does not account for confounding variables (pre-intervention pain and natural history of disease).

## 2. Research Objectives


Derive the strength of the relationship between baseline pain variability and relief while controlling for the effects of pre-intervention pain and natural history between treatment groups.

## 3. Methods

- Longitudinal pain data were obtained from two clinical trials (Placebo I and Placebo II):
  - Placebo I:
    - 18 Controls: 46 years ± 14
    - 43 Placebo-treated patients: 46 years ± 13
  - Placebo II:
    - 11 Controls: 57 years ± 12
    - 32 Placebo-treated patients: 57 years ± 9
    - 30 Drug-treated patients: 52 years ± 14
- Used multiple regression model with linear contrasts to isolate treatment effects:
  - post** ~ **pre** + **group**\***sd**
    - post**: post-intervention score
    - pre**: pre-intervention score
    - group**: treatment group
    - sd**: baseline pain variability
- Obtained semi-partial correlations between baseline pain variability and relief from multiple regression model


## 4. Results

		$r_{sp}$ (CI)
<b>Placebo I</b>	No treatment (n = 18)	-0.16 (-0.39, 0.08)
	Placebo (n=43)	0.13 (-0.08, 0.37)
<b>Placebo II</b>	No treatment (n=11)	0.08 (-0.11, 0.31)
	Placebo (n=32)	0.01 (-0.15, 0.20)
	Drug (n=30)	-0.11 (-0.26, 0.06)



**Figure 1. Adjusted post-intervention pain as a function of  $SD_{baseline}$  and group.**

We fit a linear regression to each study, which modeled post-intervention pain as a function of pre-intervention pain,  $SD_{baseline}$ , and group. Here, we depict the adjusted relationship between  $SD_{baseline}$  and post-intervention pain (on the right) after adjusting for pre-intervention pain. In Placebo I, the “no treatment” group has a weak negative correlation; however, this is driven by a single data point (see Figure 2); the “placebo” group’s  $SD_{baseline}$  is not correlated with post-intervention pain. In Placebo II, the “no treatment” and “placebo” groups show a weak, positive relationship whereas the “drug” group exhibits approximately no relationship. The raw, semi-partial correlations are included on the left.



**Figure 2. Influence of individual patients on the semi-partial correlations.**

Each point represents the semi-partial correlation when patient  $x$  is removed from the analysis. This leave-one-out analysis reveals that in both Placebo I and Placebo II, there was one participant who strongly drove the results (red points). Removing the individual in Placebo I tends to produce semi-partial correlation coefficients that are much closer to zero for both groups. Removing the individual in Placebo II to decrease the no treatment semi-partial correlation and increase the placebo semi-partial correlation. In both cases, our conclusions are unaffected since appreciable, negative semi-partial correlations do not appear in the placebo groups.

## 5. Conclusions

- The relationship between pain variability and relief is weak and inconsistent.
- Pain variability should not be used as a univariate predictor of relief in any group of a clinical trial; may hold *some* value as a covariate to improve statistical efficiency if it is able to capture variance.
- Multivariable approached can be generalized to other analyses, and may provide unique information relative to standard univariable analyses.

## 6. Acknowledgements

This work is funded by the National Institutes of Health (P50DA044121-01A1). This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1324585.